Healthcare - Biotechnology - NASDAQ - US
$ 44.83
-3.9 %
$ 1.71 B
Market Cap
-10.05
P/E
INCOME STATEMENT
17.4 M
REVENUE
-143 M
OPERATING INCOME
-136 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Tarsus Pharmaceuticals, Inc.
| Revenue | 17.4 M |
| Cost Of Revenue | 1.59 M |
| Gross Profit | 15.9 M |
| Operating Expenses | 159 M |
| Operating Income | -143 M |
| Other Expenses | -7.26 M |
| Net Income | -136 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 17.4 | 25.8 | 57.0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 1.6 | 1.0 | 2.1 | 0.2 | 74 K | 1 K |
| Gross Profit | 15.9 | 24.9 | 55.0 | (0.2) | 74 K | 1 K |
| OPERATING INCOME | ||||||
| Operating Expenses | 159.0 | 87.6 | 67.1 | 27.0 | 4.3 | 1.4 |
| Selling, General and Administrative Expenses | 108.7 | 44.9 | 25.4 | 8.2 | 1.1 | 0.4 |
| Research and Development Expenses | 50.3 | 42.6 | 41.7 | 18.8 | 3.2 | 0.9 |
| Operating Income | (143.2) | (62.7) | (12.2) | (27.0) | (4.3) | (1.4) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 3.3 | 2.2 | 0 | 0.2 | 40 K | 0 |
| Total Other Income | 7.3 | 0.6 | (1.6) | 0.2 | (0.4) | 32 K |
| Pre-Tax Income | (135.9) | (62.1) | (13.8) | (26.8) | (4.7) | (1.3) |
| NET INCOME | ||||||
| Tax Provision | 0 | 4 K | 55 K | 1 K | 1 K | 1 K |
| Net Income | (135.9) | (62.1) | (13.8) | (26.8) | (4.7) | (1.3) |
| EPS | 4.62 | 2.52 | 0.67 | 1.32 | 0.24 | 0.31 |